by Cell and gene therapy involves introducing genetic material or living cells into patients’ bodies to fight diseases. 3D bioprinting techniques enable precise placement of cellular material or therapeutic substances to promote healing or regeneration. In cell and gene therapy, 3D bioprinting allows intricate arrangements of multiple cell types in scaffolds that can be implanted in the body. Researchers are exploring ways to 3D print tissue substitutes using stem cells for conditions like cartilage or bone damage. The technology also shows promise for developing personalized grafts or drug delivery systems.
The global cell and gene therapy market is estimated to be valued at US$ 18.29 Bn in 2023 and is expected to exhibit a CAGR of 19. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Advancements in 3D bioprinting are fueling opportunities in cell and gene therapy. Researchers can now print complex 3D tissue structures using a variety of cell types arranged in anatomically accurate patterns. This mimics natural tissues better than traditional methods and enables regenerating more complex organs. Scientists are working on developing skin, cartilage and bone grafts through 3D bioprinting. The technique also allows engineering mini-organs or organoids to safely test new cell and gene therapies. As 3D bioprinting capabilities increase in precision and complexity, they are set to accelerate development and commercialization of cell and gene therapy products in the coming years.
Porter’s Analysis
Threat of new entrants: The Global Cell And Gene Therapy Market Size requires large investments in R&D to develop new therapies, receive regulatory approval, and build manufacturing facilities. This acts as a barrier to entry for new companies.
Bargaining power of buyers: Individual patients have little bargaining power as they rely on therapy providers for treatment. However, large insurance companies and governments can negotiate on price and influence market competition.
Bargaining power of suppliers: Key raw material and service suppliers including vector material manufacturers, contract development and manufacturing organizations (CDMOs) hold some power due to specialized expertise and infrastructure required.
Threat of new substitutes: No close substitutes currently exist for cell and gene therapies targeting specific diseases. New therapies in development possess similar therapeutic properties with potential to capture market share.
Competitive rivalry: The market currently sees increasing competition as major players invest in cell and gene therapy development and manufacturing scale-up. Partnerships are also common to access complementary capabilities and technologies.
Key Takeaways
The global cell and gene therapy market is expected to witness high growth. Driven by increasing prevalence of cancer and other chronic diseases, growing demand for personalized medicine, and continuous technological advancements in development and manufacturing, the market size is projected to reach US$ 63.49 Bn by 2030 from US$ 18.29 Bn in 2023.
Regional analysis:
North America currently dominates the market due to supportive regulatory environment and large healthcare investments. However, Asia Pacific is emerging as a lucrative region due to rising research investment, improving regulatory guidelines, and growing disease burden. Countries like China and Japan are expected to offer significant opportunities.
Key players: Key players operating in the cell and gene therapy market are Johnson & Johnson, Medtronic plc, Stryker Corporation, Zimmer Biomet Holdings, Inc., Smith & Nephew plc, NuVasive, Inc., Globus Medical, Inc., Wright Medical Group N.V., Arthrex, Inc., DJO Global, Inc., Össur hf., CONMED Corporation, Breg, Inc., Orthofix Medical Inc., Bioventus LLC. These companies are focused on expanding their manufacturing facilities and capabilities through acquisitions and partnerships.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
